Stem Cell Society Singapore
  • Home
  • Our Society
    • Office Bearers & Exco
    • Cell Therapy Focus Group
  • SCSS Symposium 2022
    • Programme
    • Organizing Committee
    • Poster Guide 2022
    • Exhibition Hall 2022
    • Registration
    • Supporters 2022
  • Membership
  • Events
    • AGM 2022
    • Upcoming Events
    • Past SCSS Events
      • Past SCSS Symposia
        • SCSS Symposium 2021
          • Organizing Committee
          • Speakers
          • Programme
          • Supporters
        • SCSS-JSRM 2020
          • Supporters 2020
          • Organizing Committee 2020
        • SCSS-ISCT 2019
          • Supporters
        • EMBO Workshop 2018
        • SCSS Symposium 2017
        • SCSS Symposium 2016
        • Symposia before 2016
  • Resources
    • Awards
      • SCSS Dr. Susan Lim Award
    • Fellowships
      • Overseas Travel Fellowship Programme
      • SCSS Symposium Fellowships
    • Information on Stem Cells
    • Job Market
  • Contact
  • Home
  • Our Society
    • Office Bearers & Exco
    • Cell Therapy Focus Group
  • SCSS Symposium 2022
    • Programme
    • Organizing Committee
    • Poster Guide 2022
    • Exhibition Hall 2022
    • Registration
    • Supporters 2022
  • Membership
  • Events
    • AGM 2022
    • Upcoming Events
    • Past SCSS Events
      • Past SCSS Symposia
        • SCSS Symposium 2021
          • Organizing Committee
          • Speakers
          • Programme
          • Supporters
        • SCSS-JSRM 2020
          • Supporters 2020
          • Organizing Committee 2020
        • SCSS-ISCT 2019
          • Supporters
        • EMBO Workshop 2018
        • SCSS Symposium 2017
        • SCSS Symposium 2016
        • Symposia before 2016
  • Resources
    • Awards
      • SCSS Dr. Susan Lim Award
    • Fellowships
      • Overseas Travel Fellowship Programme
      • SCSS Symposium Fellowships
    • Information on Stem Cells
    • Job Market
  • Contact
Search
Full Tentative Programme (13-15 November)

Day 1, 13 November 2019

Welcome & Opening of Symposium

 

8:30 – 8:45      Welcome Address, Shigeki Sugii, Simon Cool, Co-Chairs of Organizing Committee

                        Introduction to the Singapore Cell Therapy Manufacturing Programmes

8:45 – 8:55                  Allogeneic Stem Cell Manufacturing (ASTEM)

Simon Cool, Institute of Medical Biology, A*STAR

8:55 – 9:05                  Integrated Manufacturing Programme for Autologous Cell Therapy (IMPACT)

John Connolly, Institute of Molecular and Cell Biology, A*STAR

9:05 – 9:15                  Critical Analytics for Manufacturing of Personalized-Medicine Programme (CAMP)

Krystyn van Vliet, MIT and Singapore-MIT Alliance for Research & Technology

 

9:15 – 10:00    KEYNOTE LECTURE (Chair: Steve Oh, BTI, Singapore)

 

Genetically engineered immunity for cancer: the development and global regulatory approvals of chimeric antigen receptor (CAR) T cells and what’s coming next

Bruce Levine, University of Pennsylvania, USA

 

Session 1. Stem Cell Therapy

                        Chair: Simon Cool, Institute of Medical Biology, Singapore

 

10:00-10:20     Long term clinical outcomes of stem cell therapy in cartilage repair: Are we ready for the next step?

Francis KL Wong, Duke-NUS-Medical School, Singapore

 

10:20 – 10:50  MORNING TEA BREAK                    

 

Session 1 cont. Stem Cell Therapy

                       

10:50 – 11:10  Establishing the National Cell Therapy Program for process development and clinical manufacturing of cell & gene therapy products in Singapore

Lip Kun Tan, National University Hospital, Singapore  

 

11:10 – 11:30  Stem cell expansion of cord blood graft” vs “bridging support with 3rd party hematopoietic stem/progenitor cells

Satoshi Takahashi, University of Tokyo, Japan

 

11:30 – 11:45  Short talk: The Influence of the amniotic fluid stem cell secretome on cardiomyocyte cellular behaviour

                        Marek Kukumberg, National University of Singapore

 

11:45 – 12:00  Short talk: Long-term culture of human pancreatic progenitors: an alternative source of insulin-secreting beta cells

                        Jamie Trott, Institute of Medical Biology, Singapore

                       

12:00 – 12:20  Cardiovascular progenitors for heart regeneration in preclinical models

Lynn Yap, Duke-NUS Medical School, Singapore  

 

12:20 – 12:35  Short talk: Generation of induced motor neurons (iMNs) from human fibroblasts for cell therapy in spinal cord injury model

                        Hyunah Lee, Ulsan National Institute of Science and Technology, Korea

 

12:35 – 12:55  Softer, faster, better! – Substrate mechanics drives superior somatic cell reprogramming outcomes

Justin Cooper-White, Australian Institute for Bioengineering and Nanotechnology, Australia  

 

12:55 – 14:15  LUNCH BREAK                      


 

 

Session 2. Manufacturing and Quality Control

                        Co-Chairs:

Anthony Davies, Dark House Consulting, USA

Shin Kawamata, Foundation for Biomedical Research & Innovation, Japan

 

14:15 – 14:35  Effective & cost-effective, but unaffordable? The future of cell and gene therapy

Anthony Davies, Darkhouse Consulting, US  

                       

14:35 – 14:55  Bringing immune cell therapies to patients, innovative solutions for CAR T manufacturing, enabling scalability and cost reduction

Ohad Karnieli, ATVIO, Israel

 

14:55 – 15:15  Closing the loop: a software hypervisor to direct a structured, data science approach to cell process development

                        Drew Titmarsh, Scaled Biolabs, USA  

 

15:15 – 15:35  Future of transfusion medicine – Human induced pluripotent stem cells derived blood?

Jaichandran Sivalingam, Bioprocessing Technology Institute, Singapore  

 

15:35 – 15:50  Short talk: Ascorbate is required for the specification of human mesenchymal stem cells from human pluripotent stem cells for cartilage repair via ascorbate/iron-dependent demethylase

                        Tong Ming Liu, Institute of Molecular and Cell Biology, Singapore 

 

15:50 – 16:10  Nature inspired DMSO-, protein-, serum-free and chemically defined biopreservation solution, new horizon of precision in cell manufacturing and processing

                        Mark Kline, X-Therma, USA

 

16:10 – 16:40  AFTERNOON TEA BREAK               

 

 

16:40 – 17:00  In process monitoring for mass production of pluripotent stem cells

                        Shin Kawamata, Foundation for Biomedical Research & Innovation, Japan  

 

17:00 – 17:20  Automated cell expansion: Trends & outlook of critical technologies

May-Win Naing, Singapore Institute of Manufacturing Technology, Singapore  

 

17:20 – 17:40  Regeneus’ novel allogeneic stem cell platform for Osteoarthritis

                        Charlotte Morgan, Regeneus, Australia  

 

17:40 – 17:55  Short talk: Sub-confluent culture of human mesenchymal stem cells on biodegradable polycaprolactone microcarriers enhances bone healing of rat calvarial defect

                        Alan Tin-Lun Lam, Bioprocessing Technology Institute, Singapore

                       

17:55 – 18:40  Panel discussion

                        Panellists: C Morgan, MW Naing, O Karnelli, M Kline, D Titmarsh

                        Moderators: A. Davies and S. Kawamata

                                   

END OF DAY 1                       

 

 


Day 2, 14 November 2019

 

Session 3. Business of Cell & Gene Therapy

                        Chair: Steve Oh, Bioprocessing Technology Institute, Singapore

           

08:30-08:50   Developing allogeneic cellular immunotherapies with iPSC technology

Wen Bo Wang, Fate Therapeutics, USA  

 

08:50-09:10   Radically simplifying scale-up and clinical translation of hMSCs and extracellular vesicles

Mayasari Lim, RoosterBio Inc, USA  

           

09:10-09:25   Short talk: Characterization and application of size-dependent mesenchymal stem cell subpopulations separated using label-free microfluidics

                        Yin Lu, Singapore-MIT Alliance in Research and Technology, Singapore

 

09:25-09:45   Characterization of extracellular vesicles produced by human mesenchymal stromal cells in an improved extracellular vesicle-free medium

Arthur Sampaio, STEMCELL Technologies, Canada

`

09:45-10:05   Development of an injectable cartilage gel using chondrogenic progenitor cells

Bryan Choi, ATEMs, Korea 

 

 

10:05-10:35   MORNING TEA BREAK                 

 

 

10:35-10:55   Commercialization of advanced allogeneic cell therapy product in Korea and beyond

                        Antonio Lee, Medipost, Korea  

 

10:55-11:15   Continuous bioprocessing platform for CAR T

                        Xiangliang Lin, Esco Aster, Singapore  

 

11:15-11:35   The patient in the incubator: the cytocentric approach to avoiding suboptimal transients

                        Alicia Henn, Biospherix Ltd, USA

 

11:35-11:55   Pooled mesenchymal stromal cells – a potential break through therapy for critical limb ischemia (CLI) Management

                        Pawan Gupta, Stempeutics, India

                       

11:55-12:35   Panel discussion

Panellists: B Levine, M Lim, A Sampaio, B Choi, XL Lin, A Henn, P Gupta

Moderators: WB Wang & T Lee

 

12:35-14:00   LUNCH BREAK                   

 

 


 

 

Session 4. Responsible Pathways to Translation with Cell Therapies

                        Chair: Tamra Lysaght, National University of Singapore

 

14:00-14:05   Introduction

Tamra Lysaght, National University of Singapore, Singapore  

 

14:05-14:25   The use of professional disciplinary systems to regulate innovation: lessons from stem cell practice in Australia

Cameron Stewart, University of Sydney, Australia   

 

14:25-14:45   The oversight of clinical innovation in a medical marketplace

Wendy Lipworth, University of Sydney, Australia   

 

14:45-15:05   Expedited regulatory pathways for stem cell-based products in Malaysia: ethical and legal considerations

                        Mohammad Firdaus Bin Abdul Aziz, University of Malaya, Malaysia  

 

15:05-15:20   Short Talk: Autologous cell treatments: who owns the cells?

                        Patrick Foong, Western Sydney University, Australia

 

15:20-15:40   Regulatory updates on cell and gene therapy products in Singapore

Lee Lee Ong, Health Sciences Authority, Singapore

 

 

15:40-16:10   AFTERNOON TEA BREAK (hosted by BIOSPHERIX)             

 

 

16:10-16:30   Making the unproven proven

Mickey Koh, St George’s Hospital, UK  

 

16:30-17:20   Panel discussion

                        Panellists: C Stewart, W Lipworth, F Aziz, P Foong, LL Ong, M Koh

                        Moderator: T Lysaght

 

17:20-18:05   KEYNOTE LECTURE (Chair: Ray Dunn, IMB, Singapore)

 

The evolution and challenges introducing cell-based therapies into burn care and scar therapy

Fiona Wood, Royal Perth Hospital, Australia

 

18:05-20:00   POSTER SESSION WITH WINE & CHEESE                

                       

END OF THE DAY 2                       

 

 


Day 3, 15 November 2019

 


Session 5. Immuno & Gene Therapy

                        Chair: John Connolly, Institute of Molecular and Cell Biology, Singapore

 

09:00-09:25   Virus specific T cells as platform for solid tumor immunotherapy

John Connolly, Institute of Molecular and Cell Biology, Singapore

                       

09:25-09:40   Short talk: FOXP3 gene editing towards autologous stem cell therapy to cure IPEX Syndrome

Esmond Lee, Stanford University, USA

 

09:40-10:05   Gamma Delta T cells for anti-cancer immunotherapy

                        Shu Wang, National University of Singapore, Singapore  

 

 


10:05-10:35   MORNING TEA BREAK                 

 


10:35-11:00   T cell therapy as a localized modulator of tumor immune environment

Antonio Bertoletti, Duke-NUS Medical School, Singapore

 

11:00-11:15   Short talk: Characterisation of novel human genomic safe harbours for transgene expression

                        Matias Autio, Genome Institute of Singapore, Singapore

 

11:15-11:40   Expansion of human tumor infiltrating γδ T cells for cancer therapy

Michael Lotze, University of Pittsburgh, USA

 

 


11:40-13:15               LUNCH BREAK                   

 


 

 


Session 6. Advanced Technologies

                        Chair: Karl Tryggvason, Duke-NUS Medical School, Singapore

 

13:15-13:35   The Science of stem cell therapy – parameters affecting dosing and efficacy

Andre van Wijnen, Mayo Clinic, USA

 

13:35-13:50   Short talk: Metformin affects pancreatic differentiation from human embryonic stem cells

                        Adrian Kee Keong Teo, Institute of Molecular and Cell Biology, Singapore

                       

13:50-14:10   Cellular therapy for burns/skin injuries: Laminin-based epidermal keratinocytes culture system in xeno-free and chemically defined condition

                        Monica Tjin, Duke-NUS Medical School, Singapore  

 

14:10-14:30   Minimizing immunogenicity of iPS cells by custom disruption of HLA genes utilizing CRISPR-Cas9 genome editing: Towards 2nd generation iPS cell stock for cost-effective cell therapy

Akitsu Hotta, Kyoto University, Japan 

 


14:30-15:00   AFTERNOON TEA BREAK                       

 


15:00-15:20   Manufacturing cell therapies with predictive therapeutic outcomes: Case studies in critical quality attributes for stem & stromal cell therapies

Krystyn J. Van Vliet, MIT and Singapore-MIT Alliance for Research & Technology

 

15:20-15:40   Astrocytes derived from spinal muscular atrophy (SMA) patients are hyper-reactive and exacerbate neuronal degeneration

Lawrence Stanton, Qatar Biomedical Research Institute, Qatar

                       

15:40-16:00   Endothelial instability predisposes ischemic stroke patients to recurrent vascular events

Christine Cheung, Nanyang Technological University, Singapore  

 

16:00-16:15   Short talk: Retina specific laminins model inter-photoreceptor matrix to drive differentiation of photoreceptors from human pluripotent stem cells

                        Hwee Goon Tay, Duke-NUS Medical School, Singapore

 

16:15-16:45   DR SUSAN LIM AWARD FOR OUTSTANDING YOUNG INVESTIGATOR 2019 LECTURE (Introduction: Ray Dunn, President SCSS)

 

Global translation in early embryos and embryonic stem cells depends on the essential transcription factor PRDM10

                        Daniel Messerschmidt, Institute of Molecular and Cell Biology, Singapore

 


16:45-17:00   AWARDS, CLOSING REMARKS & FAREWELL

 

END OF DAY 3 & END OF SYMPOSIUM                       

 


Organized by:
​

Picture
Copyright © 2019 Stem Cell Society Singapore    Sitemap   Terms & Conditions   Privacy Statement
Proudly powered by
Weebly
  • Home
  • Our Society
    • Office Bearers & Exco
    • Cell Therapy Focus Group
  • SCSS Symposium 2022
    • Programme
    • Organizing Committee
    • Poster Guide 2022
    • Exhibition Hall 2022
    • Registration
    • Supporters 2022
  • Membership
  • Events
    • AGM 2022
    • Upcoming Events
    • Past SCSS Events
      • Past SCSS Symposia
        • SCSS Symposium 2021
          • Organizing Committee
          • Speakers
          • Programme
          • Supporters
        • SCSS-JSRM 2020
          • Supporters 2020
          • Organizing Committee 2020
        • SCSS-ISCT 2019
          • Supporters
        • EMBO Workshop 2018
        • SCSS Symposium 2017
        • SCSS Symposium 2016
        • Symposia before 2016
  • Resources
    • Awards
      • SCSS Dr. Susan Lim Award
    • Fellowships
      • Overseas Travel Fellowship Programme
      • SCSS Symposium Fellowships
    • Information on Stem Cells
    • Job Market
  • Contact